Full Press Release Details
Investor Presentation
Joe Burnett, President & CEO June 2018
Statements herein concerning MRI Interventions, Inc. (the
"Company") plans, growth and strategies may include forward-looking statements within the context of the federal securities
laws. Statements regarding the Company's future events, developments and future performance, as well as management's expectations,
beliefs, plans, estimates or projections relating to the future, are forward-looking statements within the meaning of these laws.
Uncertainties and risks may cause the Company's actual results to differ materially from those expressed in or implied by forward-looking
statements. Particular uncertainties and risks include those relating to: the Company's ability to obtain additional financing;
estimates regarding the sufficiency of the Company's cash resources; future revenues from sales of the Company's ClearPoint
System products; and the Company's ability to market, commercialize and achieve broader market acceptance for the Company's
ClearPoint System products. More detailed information on these and additional factors that could affect the Company's actual
results are described in the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year
ended December 31, 2017, which has been filed with the Securities and Exchange Commission, and the Company's Quarterly Report
on Form 10-Q for the quarter ended March 31, 2018, which the Company intends to file with the Securities and Exchange Commission
on or before May 15, 2018.
Only a Fraction of Patients with Debilitating Neurological
being Treated Surgically Today
Neurological Disorders
Parkinson's Epilepsy
Tumor ICH Surgical Procedures
numbers are based on either market research conducted by a third party on behalf of
MRI Interventions or research conducted by MRI Interventions
of publicly available sources.
Minimally Invasive Procedures has
has always had two things in common;
are ENABLED BY LIVE IMAGE GUIDANCE
Traditional Stereotactic
Neurosurgery is Limited
do not show structures of the brain
Metallic Navigation Frames are not compatible inside an MRI Magnet
ClearPoint Neuro Navigation System Platform
The only Neuro-Navigation
System with Sub-millimeter' Accuracy
ClearPoint Procedure
Entry and Trajectory
Our Value: We DECIDE,
GUIDE & CONFIRM the most
challenging neurosurgery
therapies Decide 1 Advanced Planning Software and Fusion Algorithms enable Fly Through' entry point and trajectory
planning the day of the procedure using live MRI Images Guide 2 Uniquely enable changes to trajectory live, in the MRI, to accommodate
anatomical shift or procedural challenges to deliver pinpoint or CLEARPOINT accuracy Confirm 3 Take final images and measurements
of the targeting cannula in place to confirm the patient had the best possible chance at success before ending the therapy procedure
enables CHOICE of Precision-Guided
for DBS, LITT, Biopsy and Drug Delivery
Company for Precision MRI-Guided Therapy
- MRI Interventions:
Leader in Precision MRI-Guided Therapy
that allows delivery of therapies to the brain with pinpoint accuracy under live MRI Guidance
can take place in the MRI suite, reducing the risk of hospital acquired infections and complications
Intellectual Property position: 70+ issued US patents, 45 international
Growth Fueled By Expanding Installed Base and Increased Utilization
systems in the U.S. at leading Neurosurgery Hospitals and Teaching Programs
system placement enables razor - razorblade disposable product sales
count continues to grow; 43% CAGR (est.) the past four years
direct sales channel totaling 16 people supporting cases in the U.S.
Platform into Adjacent Areas to Address Additional Unmet Medical Needs
Biologics and Drug Partners using MRIC for delivery in therapy trials
developed Neuro-Aspiration device will add therapy to our sales team portfolio
and New addressable markets > $1B in potential
Platform MRI Interventions, Inc.: Headquarters: Irvine, CA Employees: 39 (16 Sales, 14 Product Dev.) 2017
Revenue: $7.4 Million Market Cap: $23 Million Cash: $7.5 million Gross margin: 63.7% Financial data as of March 31, 2018
quarter end Share data as of June 1, 2018 Key Products: ClearPoint SmartFrame SmartFlow Platform &
Accessories Canulae Mix FDA / CE Marked Platforms 79 U.S. Patents, 27 Pending Applications Increasing Market Adoption:
43% Case CAGR 700 600 500 400 300 200 100 0 2013 2014 2015 2016 2017 Proven Revenue Growth: 32%
CAGR $8,000 $7,000 $6,000 $5,000 $4,000 $3,000 $2,000 $1,000 $ millions $- 2013 2014 2015 2016 2017
/ Service Other 2018 MRI INTERVENTIONS, INC. | 9
User Base of Leading Neurosurgeons ClearPoint Is Installed in 53 Top US Hospitals and Growing UC San Francisco San Francisco
VA Stanford Univ UCSF Benioff Childrens USC
Univ of Colo Univ of Utah Univ of Arizona Cook Children's MD Anderson Methodist Hosp Texas Children's
Hosp Riverside Nationwide Children's Children's Mercy Kansas
Univ Med Center Univ of Wisconsin Spectrum Health Ohio State Univ Univ of Cincinnati Univ of Michigan
Univ of Minnesota Med Ctr Brigham & Women's Boston Children's Yale Univ Univ
of Pitt Med Center Memorial Sloan Kettering Hackensack Univ Med Center Cornell Central Du Page Nat. Institutes of Health Nat Children's
Hospital Children's Hosp of Philadelphia Univ of Virginia Emory University Carillion Duke University Children's of
Alabama CHOA Scottish Rite Willis Knighton Mayo Clinic Jacksonville Miami Children's Strong Commercial Sales and Clinical
Support Teams in Place
Our MRI-Guided Therapy
Platform is Currently Being Used to: Implant Neuro Stimulation Leads from: Medtronic - St. Jude Medical - Boston Scientific
- NeuroPace Place Laser Ablation Probes from: - Medtronic-Visualase - Monteris Medical MRIC Platform Runs on All
Major Scanners: - Siemens - GE - Philips - IMRIS
Potential for Procedures MRIC Growth Cntribution New Therapy Product Sales Direct & Though Partnerships ClearPoint &
Caths in Drug Therapy Trials & Commercial Strategic & Focused Expansion to new geographies either direct or through partners
2+ Therapy Products & Opportunities to Distribute (e.g. ICH Clot Extraction) 5+ Current Phase I Trials Tumor Biopsy &
Ablation Included 4 Below 50,000+ 3 50,000+ 2 12,500+ Growth from New Markets Growth from Existing Markets ClearPoint
Platform Sales Into Existing Device Markets LITT and NeuroPace for Epilepsy Deep Brain Stimulation (DBS) for Parkinson's
28,000+ 1 15,000+ 2017 Base Revenue 2017 2022 Target Indications of > 150,000 procedures per year represents Potential
Addressable Market for MRIC of $1B+ Note: Market sizes for brain tumor, ICH are Pancreatic cancer are incidence numbers
because of the nature of those diseases. Prevalence numbers are based on either market research conducted by a third party on
behalf of MRI Interventions or research conducted by MRI Interventions of publicly available sources.
Electrode Placement for Deep Brain Stimulation Laser
Catheter Placement for Ablation Procedures Key Strategies & Tactics for 2018: - Add 8-10 new centers from existing
funnel via capital sales and evaluation agreements - Publish Best Practices' workflows to get procedures predictably
under four hours enabling two procedures a day in MRI scanners instead of one, present to entire installed base - Pursue
clinical pathway for an Asleep DBS' Indication to allow more substantial marketing, training and education of the
benefits of asleep procedures which patients desire
ClearPoint 2.0 Image Fusion Feature (Pending FDA Clearance)
Designed to reduce procedure time by fusing pre-procedure planning to real-time MRI imaging
Precise, Quantifiable Drug Delivery ClearPoint
2.0 Software (Pending FDA Clearance)Key
Strategies & Tactics for 2018: - Assign a Sales Portfolio Manager' to proactively build our brand as the